Hypercalcemic Disorders Hasan AYDIN MD Yeditepe University Hospital

  • Slides: 34
Download presentation
Hypercalcemic Disorders Hasan AYDIN, MD Yeditepe University Hospital Endocrinology and Metabolism

Hypercalcemic Disorders Hasan AYDIN, MD Yeditepe University Hospital Endocrinology and Metabolism

Etiologies of Hypercalcemia Increased GI Absorption Milk-alkali syndrome Elevated calcitriol Vitamin D excess Excessive

Etiologies of Hypercalcemia Increased GI Absorption Milk-alkali syndrome Elevated calcitriol Vitamin D excess Excessive dietary intake Granulomatous diseases Elevated PTH Hypophosphatemia Increased Loss From Bone Increased net bone resorption Elevated PTH Hyperparathyroidism Malignancy Osteolytic metastases PTHr. P secreting tumor Increased bone turnover Paget’s disease of bone Hyperthyroidism Decreased Bone Mineralization Elevated PTH Aluminum toxicity Decreased Urinary Excretion Thiazide diuretics Elevated calcitriol Elevated PTH

ETIOLOGY Approx. 80% of all cases are caused by Malignancy or Primary Hyperpathyroidism V

ETIOLOGY Approx. 80% of all cases are caused by Malignancy or Primary Hyperpathyroidism V I T A M I N S Vitamins Immobilization Thyrotoxicosis Addison’s disease Milk-alkali syndrome Inflammatory disorders Neoplastic related disease Sarcoidosis T R A P Thiazide, other drugs - Lithium Rabdomyolysis AIDS Paget’s disease, Parental nutrition, Pheochromocytoma, Parathyroid disease

CLASSIFICATION PTH-Dependent Hypercalcemia Primary hyperparathyroidism Tertiary hyperparathyroidism Familial hypocalciuric hypercalcemia Lithium-asociated hypercalcemia

CLASSIFICATION PTH-Dependent Hypercalcemia Primary hyperparathyroidism Tertiary hyperparathyroidism Familial hypocalciuric hypercalcemia Lithium-asociated hypercalcemia

CLASSIFICATION PTH-Independent Hypercalcemia Neoplasms Hyperthyroidism PTHr-P dependent Adrenal insufficiency Other humoral syndromes Renal failure

CLASSIFICATION PTH-Independent Hypercalcemia Neoplasms Hyperthyroidism PTHr-P dependent Adrenal insufficiency Other humoral syndromes Renal failure Osteolytic metastases and İmmobilization multiple myeloma Jansen’s metapyseal Excess. Vitamin chondrodysplasia D/1, 25(OH)2 D Drugs Vitamin D ingestion 1, 25(OH)2 D intoxication Toicaşl vitamin D analogues Sarcoidosis and other granulomatous diseases Williams syndrome Vitamin A intoxication Milk alkali syndrome Thiazide diuretics Theophylline

CLINICAL MANIFESTATIONS GI- Anorexia, Nausea, Vomiting, Constipation and rarely acute Pancreatitis. CVS- Hypertension, shortened

CLINICAL MANIFESTATIONS GI- Anorexia, Nausea, Vomiting, Constipation and rarely acute Pancreatitis. CVS- Hypertension, shortened QT interval RENAL- Thirst, Polyuria, Polydipsia, and occasionally Nephrocalcinosis. CNS- Cognitive difficulties, Apathy, Drowsiness, Obtundation, or even Coma. -Anxiety, Depression, Psychosis Ectopic Calcifications- Nephrocalcinosis, calcifications of blood vessels, band keratopathy

SYMPTOMS More than 50% of all patients with primary hyperparathyroidism are asymptomatic when hypercalcemia

SYMPTOMS More than 50% of all patients with primary hyperparathyroidism are asymptomatic when hypercalcemia is first discovered.

COMPLICATIONS Sinus bradycardia Increase in the degree of a heart block Cardiac arrhythmia Hypertension

COMPLICATIONS Sinus bradycardia Increase in the degree of a heart block Cardiac arrhythmia Hypertension Pancreatitis Peptic ulcer disease Nephrolithiasis Accelerated vascular calcification

Diagnostic Yield in Hypercalcemia Investigation Potential Information Full Blood Count Anemia suggest non-parathyroid etiology

Diagnostic Yield in Hypercalcemia Investigation Potential Information Full Blood Count Anemia suggest non-parathyroid etiology if renal function normal ESR Usually over 80 in myeloma Plasma chloride Upper normal in hypepararthyroidism Plasma bicarbonate Low normal in hypepararthyroidism Creatinine Significantky raised in tertiay hyperparathyroidism of renal failure. Moderately raised in renal impairement secondary to hypercalcemia Plasma protein electrophoresis Monoclonal band suggest myeloma Urinary immunelectrophoresis Presece of light chain suggest myeloma Plasma phosphate Low normal in primary hyperparathyroidism unless renal function impaired Plasma PTH Upper normal or raised in hyperparathyroidism Suppressed with other causes of hypercalcemia Steroid suppression test Sarcoid hypercalcemia alwasy suppress, hyperparathyroid never, malignanat causes occasionally 24 h urine calcium Decreased in FHH Chest X-ray Neoplasms, hilar LAP in sarcoidosis Isotope bone scan ‘Hot spots’ suggest metastases X-ray hands Subperiosteal erosions suggest hyperparathyroidism

HYPERCALCEMIA SERUM CALCIUM > 10. 6 Determine wheather hypercalcemia is real, measure ionized Ca

HYPERCALCEMIA SERUM CALCIUM > 10. 6 Determine wheather hypercalcemia is real, measure ionized Ca adjust for change in serum albumin level, careful drug hx Li, Vit D or A, Measure PTH high Hyperparathroidism PTH - N or Low Malig- prim. or mets If cause remain unclear measure Vit D Vit high consider Sarcoidosis CXR Consider other *Hyperthyroidism *Milk-alkali syndrome *Familial hypocalciuric hypercalcemia

MANAGEMENT OF SYMPTOMATIC HYPERCALCEMIA General measures Saline diuresis Specific measures Glucocorticoids Phosphate infusion Bisphonates

MANAGEMENT OF SYMPTOMATIC HYPERCALCEMIA General measures Saline diuresis Specific measures Glucocorticoids Phosphate infusion Bisphonates Calcitonin Dialysis

LOOP DIURETICS Facilitate urinary excretion of calcium By inhibiting calcium reabsorption in the thick

LOOP DIURETICS Facilitate urinary excretion of calcium By inhibiting calcium reabsorption in the thick ascending limb of the loop of Henle. Guard against volume overload Volume expansion must precede the administration of furosemide, because the drug’s effect depends on delivery of calcium to the ascending limb. Needs frequent measurement of lytes and water

 CALCITONIN Not as effective as bisphonate, tachyphylaxis quickly occurs and limits therapeutic efficacy

CALCITONIN Not as effective as bisphonate, tachyphylaxis quickly occurs and limits therapeutic efficacy MITHRAMYCIN Toxic effect limits it’s use, reserved for difficult cases of hypercalcemia that are related to malignancy GALLIUM NITRATE Need to infuse it over 5 days, nephrotoxity limits it’s use, not used frequently CORTICOSTEROIDS For myeloma, lymphoma, Sarcoidosis, or vit D toxicity decrease GI absorption, 200 -300 mg hydrocort for upto 5 days, slow response limits it’s use HEMODIALYSIS Zero or low calcium bath, In selected condition, eg-hypercalcemia

BISPHONATES Structurally related to pyrophosphate. P-C-P bound is a back bone that renders them

BISPHONATES Structurally related to pyrophosphate. P-C-P bound is a back bone that renders them resistant to phosphates. They bind to hydroxyapatite in bone and inhibit the dessolution of crystals. Their great affinity for bone and their resistance to degradation account for their extremely long half life in bone. Poor GI absorption- <10% ETIDRONATE PAMIDRONATE CLODRONATE

CHOICE OF AGENT Mild (<12 mg/dl)-Hydration with saline. Moderate(>15 mg/dl) with moderate symptoms- Bisphonate.

CHOICE OF AGENT Mild (<12 mg/dl)-Hydration with saline. Moderate(>15 mg/dl) with moderate symptoms- Bisphonate. Severe life threatening( >15 mg/dl) - Saline + Calcitonin + mithramycin, alternatively bisphonate, if steroids sensitive + steroids. Hypercalcemia secondary to malignancy- survival after the appearance of hypercalcemia is very poor -

SPECIFIC CAUSES OF HYPERCALCEMIA

SPECIFIC CAUSES OF HYPERCALCEMIA

FAMILIAL HYPOCALCIURIC HYPERCALCEMIA Autosomal dominant Inactivating mutation of calcium sensing receptor Shift in the

FAMILIAL HYPOCALCIURIC HYPERCALCEMIA Autosomal dominant Inactivating mutation of calcium sensing receptor Shift in the set point for suppression of PTH Starts at birth Serum Ca mild/moderately elevated Urinary calcium excretion low/normal Urinary CCa/CCr <0, 1 PTH normal/Slightly elevated Multiple, slightly enlarged, policlonal glands Usually asymptomatic Surgery not effective

Lithium Toxicity 5% of cases Due to: Increse in the set-point for PTH secretion

Lithium Toxicity 5% of cases Due to: Increse in the set-point for PTH secretion Increase in tubular reabsorption of calcium After years of treatment Elevation in calcium and PTH Enlargement of parathyroids After withdrawal, Ca and PTH returns normal within several months

Hypercalcemia of Malignancy Most common cause in hospitalized patients Most common in Sq. Cell

Hypercalcemia of Malignancy Most common cause in hospitalized patients Most common in Sq. Cell Ca. , Breast. Renal Bladder Ca, MM, Lymphoma Uncommon in colon and prostate ca. Occurs in the late course of malignancy Dehydration, immobilization and treatment with certain drugs contribute to or potentiate development of hypercalcemia

Hypercalcemia of Malignancy Specific causes of hypercalcemia Direct invasion of bone (local osteolysis)-20 -40%

Hypercalcemia of Malignancy Specific causes of hypercalcemia Direct invasion of bone (local osteolysis)-20 -40% Tumor production of circulating factors (PTHr. P) that osteoclastic resorption of bone (humoral hypercalcemia of malignancy)-40 -50% Ectopic production of 1, 25 (OH)2 D 3 (lymphomas) Ectopic production of PTH (Lung, Ovary, Thyroid) Concomitant malignancy and PHP or granulomatous disease Treatment with estrogen and antiestrogen (tamoxifen)

Vitamin D Intoxication >100, 000 units/day 25(OH)D level 5 -10 x high despite N/slightly

Vitamin D Intoxication >100, 000 units/day 25(OH)D level 5 -10 x high despite N/slightly elevated 1, 25(OH)2 D 3 Hypercalcemia and hypercalciuria N/V, weakness, altered consciousness Persist for weeks to months after discontinuation of medication Use of steroids (prednisone 40 -60 mg/day)

Granulomatous Diseases Hypercalcemia in 10%, hypercalciuria 50% of sarcoidosis Correlate with degree of severity

Granulomatous Diseases Hypercalcemia in 10%, hypercalciuria 50% of sarcoidosis Correlate with degree of severity and level of ACE Causes High level of 1, 25(OH)2 D 3 Overproduction of bone resorbing cytokines Production of PTHr. P Treatment with steroids (prednisone 40 -60 mg/d)

Hyperthyroidism 15 -50% of cases By direct stimulation of ostoclastic bone resorption Ca levels

Hyperthyroidism 15 -50% of cases By direct stimulation of ostoclastic bone resorption Ca levels rarely exceed 11 mg/d. L Low PTH, Low 1, 25(OH)2 D 3, Hypercalciuria

Vitamin A Intoxication >50, 000 IU/day Treatment with cis-retinoic acid or all- transretinoic acid

Vitamin A Intoxication >50, 000 IU/day Treatment with cis-retinoic acid or all- transretinoic acid Dry skin, pruritus, headache, bone pain By direct stimulation of bone resorption Treatment with hydration and steroids

Adrenal Insufficiency Causes Volume depletion with hemoconcentration Increased tubular reabsorption of calcium, Increased skeletal

Adrenal Insufficiency Causes Volume depletion with hemoconcentration Increased tubular reabsorption of calcium, Increased skeletal release of calcium Treatment Correction of volume depletion Steroids

Thiazide Diuretics Rarely cause hypercalcemia by themselves Causes ↑ renal tubular reabsorption of Ca

Thiazide Diuretics Rarely cause hypercalcemia by themselves Causes ↑ renal tubular reabsorption of Ca ↑ bone resorption activity Diuretic-induced volume depletion

Milk Alkali Syndrome Ingestion of excessive amounts of milk (calcium supplements) or soluble alkali

Milk Alkali Syndrome Ingestion of excessive amounts of milk (calcium supplements) or soluble alkali (antacids) Acute form Triad of hypercalcemia, metabolic alkalosis, renal failure Treatment with rehydration and if necessary dialysis Chronic form (Burnett syndrome) Soft tissue calcifications in kidney and nephrocalcinosis

Immobilization Increased bone resorption Hypercalciuria, ↓ PTH and 1, 25(OH)2 D 3 Bisphonates ±

Immobilization Increased bone resorption Hypercalciuria, ↓ PTH and 1, 25(OH)2 D 3 Bisphonates ± Calcitonin

Williams Syndrome Supravalvular aortic stenosis, elfin facies, mental retardation Hypercalcemia in infancy (↑ 1,

Williams Syndrome Supravalvular aortic stenosis, elfin facies, mental retardation Hypercalcemia in infancy (↑ 1, 25(OH)2 D 3) Jansen’s Metaphyseal Chondrodisplasia Short stature, hypercalcemia Similar to PHP PTH-R activating mutation

HEREDITARY PRIMARY HYPERPARATHYROIDISM SYNDROMES MEN 1 Familial Hypocalciuric Hypercalcemia Neonatal Severe Hyperparathyroidism MEN 2

HEREDITARY PRIMARY HYPERPARATHYROIDISM SYNDROMES MEN 1 Familial Hypocalciuric Hypercalcemia Neonatal Severe Hyperparathyroidism MEN 2 a Hyperparathyroidism-Jaw Tumor Syndrome

MEN 1 Parathyroid, enteropancreatic, pituitary and other tumors (85 % HP, 35 % Z-E,

MEN 1 Parathyroid, enteropancreatic, pituitary and other tumors (85 % HP, 35 % Z-E, 25 % Prolactinoma) Otosomal dominant Inactivating MEN 1 gene germ-line mutation Starting age : 25 Urinary calcium excretion normal-high High PTH Multiple abnormal glands 90 % cure after PTX

MEN 2 A Pheochromocytoma, medullary thyroid CA, mild hyperparathyroidism Activating mutation of the RET

MEN 2 A Pheochromocytoma, medullary thyroid CA, mild hyperparathyroidism Activating mutation of the RET proto- oncogene Otosomal dominant